Running Point Capital Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Running Point Capital Advisors’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$11.5K	Hold	135	–	–	﹤0.01%	169
2025 Q3	$9.8K	Hold	135	–	–	﹤0.01%	176
2025 Q2	$8.85K	Hold	135	–	–	﹤0.01%	169
2025 Q1	$9.53K	Hold	135	–	–	﹤0.01%	159
2024 Q4	$8.87K	Hold	135	–	–	﹤0.01%	146
2024 Q3	$9.53K	Hold	135	–	–	﹤0.01%	132
2024 Q2	$8.95K	Hold	135	–	–	﹤0.01%	128
2024 Q1	$9.17K	Buy	135 +90	+200%	+$5.95K	﹤0.01%	127
2023 Q4	$2.79K	Buy	+45	New	+$2.65K	﹤0.01%	148

Other funds holding IHE

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

ACM

Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Running Point Capital Advisors's IHE Position: Q4 2025 in Review

Running Point Capital Advisors held its iShares US Pharmaceuticals ETF (IHE) position steady in Q4 2025 at 135 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #169.

Running Point Capital Advisors first reported a position in IHE in Q4 2023 and has held it in 9 quarters since. 178 funds tracked by Wall St. Rank hold IHE as of Q4 2025.

Running Point Capital Advisors held 135 shares of iShares US Pharmaceuticals ETF worth $11.5K as of Q4 2025.
Running Point Capital Advisors left its iShares US Pharmaceuticals ETF share count unchanged in Q4 2025.
iShares US Pharmaceuticals ETF made up ﹤0.01% of Running Point Capital Advisors's portfolio in Q4 2025, its #169 holding.
Running Point Capital Advisors first reported a position in iShares US Pharmaceuticals ETF in Q4 2023 and has held it in 9 quarters since.
178 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2025.

Based on Running Point Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.